Tasci, Iiker <br/><br/>
Rat liver fibrosis regresses better with pegylated interferon alpha2b and ursodeoxycholic acid treatments than spontaneous recovery.  [electronic resource] 

 -  Liver international : official journal of the International Association for the Study of the Liver  Mar 2006 
 - 261-8 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1478-3223 
<br/><br/><label>Standard No.: </label>10.1111/j.1478-3231.2005.01210.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Actins--metabolism<br/>Animals<br/>Antiviral Agents--therapeutic use<br/>Apoptosis--drug effects<br/>Cholagogues and Choleretics--therapeutic use<br/>Collagenases--metabolism<br/>Drug Therapy, Combination<br/>Hydroxyproline--metabolism<br/>In Situ Nick-End Labeling<br/>Interferon alpha-2<br/>Interferon-alpha--therapeutic use<br/>Kupffer Cells--drug effects<br/>Liver Cirrhosis, Experimental--drug therapy<br/>Male<br/>Matrix Metalloproteinase 13<br/>Polyethylene Glycols<br/>Rats<br/>Rats, Sprague-Dawley<br/>Recombinant Proteins<br/>Recovery of Function<br/>Tissue Inhibitor of Metalloproteinase-1--metabolism<br/>Ursodeoxycholic Acid--therapeutic use